Tenascin-C expression and its prognostic significance in colorectal cancer

Oncology

Volumn 72, Issue 5-6, 2008, Pages 403-409

  Lundin, M ^a   Nordling, S ^a   Lundin, J ^a   Haglund, C ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Colorectal cancer; Immunohistochemistry; Tenascin C; Virtual microscopy

Indexed keywords

TENASCIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ASSESSMENT; COLORECTAL CANCER; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; TENASCIN; TUMOR MARKERS, BIOLOGICAL;

EID: 39049153701     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000113490     Document Type: Article

References (40)

1. Chiquet-Ehrismann R, Mackie EJ, Pearson CA, Sakakura T: Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell 1986;47:131-139.
2. Mackie EJ, Halfter W, Liverani D: Induction of tenascin in healing wounds. J Cell Biol 1988;107:2757-2767.
3. Riedl S, Kadmon M, Tandara A, Hinz U, Moller P, Faissner A: Tenascin-C tissue concentration in inflammatory and neoplastic diseases of the colon mucosa. Anticancer Res 1997;17:3165-3166.
4. 1 in gastric and colorectal cancers with lymph node and liver metastases. Acta Histochem 2006;108:25-35.
5. Orend G: Potential oncogenic action of tenascin-C in tumorigenesis. Int J Biochem Cell Biol 2005;37:1066-1083.
6. Orend G, Chiquet-Ehrismann R: Tenascin-C induced signaling in cancer. Cancer Lett 2006;244:143-163.
7. Tanaka K, Hiraiwa N, Hashimoto H, Yamazaki Y, Kusakabe M: Tenascin-C regulates angiogenesis in tumor through the regulation of vascular endothelial growth factor expression. Int J Cancer 2004;108:31-40.
8. Sakai T, Kawakatsu H, Hirota N, Yokoyama T, Sakakura T, Saito M: Specific expression of tenascin in human colonic neoplasms. Br J Cancer 1993;67:1058-1064.
9. Riedl S, Kadmon M, Tandara A, Hinz U, Moller P, Herfarth C, Faissner A: Mucosal tenascin C content in inflammatory and neoplastic diseases of the large bowel. Dis Colon Rectum 1998;41:86-92.
10. Natali PG, Nicotra MR, Bigotti A, Botti C, Castellani P, Risso AM, Zardi L: Comparative analysis of the expression of the extracellular matrix protein tenascin in normal human fetal, adult and tumor tissues. Int J Cancer 1991;47:811-816.
11. Sugawara I, Hirakoshi J, Masunaga A, Itoyama S, Sakakura T: Reduced tenascin expression in colonic carcinoma with lymphogenous metastasis. Invasion Metastasis 1991;11:325-331.
12. Riedl SE, Faissner A, Schlag P, Von Herbay A, Koretz K, Moller P: Altered content and distribution of tenascin in colitis, colon adenoma, and colorectal carcinoma. Gastroenterology 1992;103:400-406.
13. Hauptmann S, Zardi L, Siri A, Carnemolla B, Borsi L, Castellucci M, Klosterhalfen B, Hartung P, Weis J, Stocker G, et al: Extracellular matrix proteins in colorectal carcinomas. Expression of tenascin and fibronectin isoforms. Lab Invest 1995;73:172-182.
14. Suwiwat S, Ricciardelli C, Tammi R, Tammi M, Auvinen P, Kosma VM, LeBaron RG, Raymond WA, Tilley WD, Horsfall DJ: Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res 2004;10:2491-2498.
15. Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, Arvanitis DL, Agnantis NJ, Pavlidis N: Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer 2002;38:2362-2370.
16. Ishiwata T, Takahashi K, Shimanuki Y, Ohashi R, Cui R, Takahashi F, Shimizu K, Miura K, Fukuchi Y: Serum tenascin-C as a potential predictive marker of angiogenesis in non-small cell lung cancer. Anticancer Res 2005;25:489-495.
17. Leins A, Riva P, Lindstedt R, Davidoff MS, Mehraein P, Weis S: Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Cancer 2003;98:2430-2439.
18. Brunner A, Mayerl C, Tzankov A, Verdorfer I, Tschorner I, Rogatsch H, Mikuz G: Prognostic significance of tenascin-C expression in superficial and invasive bladder cancer. J Clin Pathol 2004;57:927-931.
19. Ioachim E, Michael M, Stavropoulos NE, Kitsiou E, Salmas M, Malamou-Mitsi V: A clinicopathological study of the expression of extracellular matrix components in urothelial carcinoma. BJU Int 2005;95:655-659.
20. Ilmonen S, Jahkola T, Turunen JP, Muhonen T, Asko-Seljavaara S: Tenascin-C in primary malignant melanoma of the skin. Histopathology 2004;45:405-411.
21. Salmenkivi K, Haglund C, Arola J, Heikkila P: Increased expression of tenascin in pheochromocytomas correlates with malignancy. Am J Surg Pathol 2001;25:1419-1423.
22. Aishima S, Taguchi K, Terashi T, Matsuura S, Shimada M, Tsuneyoshi M: Tenascin expression at the invasive front is associated with poor prognosis in intrahepatic cholangiocarcinoma. Mod Pathol 2003;16:1019-1027.
23. Sis B, Tuna B, Yorukoglu K, Kargi A: Tenascin C and cathepsin D expression in adipocytic tumors: an immunohistochemical investigation of 43 cases. Int J Surg Pathol 2004;12:11-15.
24. Wiksten JP, Lundin J, Nordling S, Lundin M, Kokkola A, von Boguslawski K, Haglund C: Tenascin-C expression correlates with prognosis in gastric cancer. Oncology 2003;64:245-250.
25. Pilch H, Schaffer U, Schlenger K, Lautz A, Tanner B, Hockel M, Knapstein PG: Expression of tenascin in human cervical cancer - association of tenascin expression with clinicopathological parameters. Gynecol Oncol 1999;73: 415-421.
26. Iskaros BF, Tanaka KE, Hu X, Kadish AS, Steinberg JJ: Morphologic pattern of tenascin as a diagnostic biomarker in colon cancer. J Surg Oncol 1997;64:98-101.
27. Emoto K, Yamada Y, Sawada H, Fujimoto H, Ueno M, Takayama T, Kamada K, Naito A, Hirao S, Nakajima Y: Annexin II overexpression correlates with stromal tenascin-C overexpression: a prognostic marker in colorectal carcinoma. Cancer 2001;92:1419-1426.
28. Kressner U, Lindmark G, Tomasini-Johansson B, Bergstrom R, Gerdin B, Pahlman L, Glimelius B: Stromal tenascin distribution as a prognostic marker in colorectal cancer. Br J Cancer 1997;76:526-530.
29. Sis B, Sagol O, Kupelioglu A, Sokmen S, Terzi C, Fuzun M, Ozer E, Bishop P: Prognostic significance of matrix metalloproteinase-2, cathepsin D, and tenascin-C expression in colorectal carcinoma. Pathol Res Pract 2004;200:379-387.
30. Riedl S, Bodenmuller H, Hinz U, Holle R, Moller P, Schlag P, Herfarth C, Faissner A: Significance of tenascin serum level as tumor marker in primary colorectal carcinoma. Int J Cancer 1995;64:65-69.
31. Hanamura N, Yoshida T, Matsumoto E, Kawarada Y, Sakakura T: Expression of fibronectin and tenascin-C mRNA by myofibroblasts, vascular cells and epithelial cells in human colon adenomas and carcinomas. Int J Cancer 1997;73:10-15.
32. Turnbull RB Jr, Kyle K, Watson FR, Spratt J: Cancer of the colon: the influence of the notouch isolation technic on survival rates. Ann Surg 1967;166:420-427.
33. Jass JR, Sobin LH: World Health Organization International Histological Classification of Tumors, ed 2. New York, Springer, 1989.
34. Cox DR: Regression models and life tables. J Roy Statist Soc 1972;B34:187-220.
35. Zirbes TK, Baldus SE, Moenig SP, Schmitz K, Thiele J, Holscher AH, Dienes HP: Tenascin expression in gastric cancer with special emphasis on the WHO-, Lauren-, and Gosekiclassifications. Int J Mol Med 1999;4:39-42.
36. Ilunga K, Iriyama K: Expression of tenascin in gastric carcinoma. Br J Surg 1995;82:948-951.
37. Dueck M, Riedl S, Hinz U, Tandara A, Moller P, Herfarth C, Faissner A: Detection of tenascin-C isoforms in colorectal mucosa, ulcerative colitis, carcinomas and liver metastases. Int J Cancer 1999;82:477-483.
38. Takeda A, Otani Y, Iseki H, Takeuchi H, Aikawa K, Tabuchi S, Shinozuka N, Saeki T, Okazaki Y, Koyama I: Clinical significance of large tenascin-C spliced variant as a potential biomarker for colorectal cancer. World J Surg 2007;31:388-394.
39. Siri A, Knauper V, Veirana N, Caocci F, Murphy G, Zardi L: Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases. J Biol Chem 1995;270:8650-8654.
40. Sakakura T, Kusakabe M: Can tenascin be redundant in cancer development? Perspect Dev Neurobiol 1994;2:111-116.